FRISCO, Texas, Nov. 9, 2015 /PRNewswire/ -- SomnoMed Limited (SOM: ASX) subsidiary, SomnoMed Canada Inc., acquired the business of Strong Dental in Leamington, Ontario, Canada. The acquisition covers all tangible and intangible assets of Strong Dental, an exclusive license to all patents linked to dental sleep devices made by Strong Dental for the treatment of sleep disordered breathing and the employment of key staff.
"The acquisition of Strong Dental in Canada will not only add a highly reputable device to our line of SomnoDent dental sleep devices, available in 26 countries, but it will also give SomnoMed its own service and logistic hub, a precondition for selling our SomnoDent® products, directly in Canada," said Dr. Peter Neustadt, Executive Chairman of SomnoMed.
Patrick Strong is the inventor of the SUAD oral device, which is manufactured by and distributed by Strong Dental in the US and Canada.
Oral appliances for the treatment of sleep disordered breathing conditions are well known amongst dentists and physicians in treating obstructive sleep apnea (OSA) patients and are used as an alternative, or in place of, CPAP therapy and/or surgery.
Strong has entered into a consultancy agreement with SomnoMed, and he will be responsible for overseeing the day to day operations of SomnoMed Canada Inc. Strong Dental uses digital technology in their production process of making models and components, which strengthens their SUAD oral appliances.
"By establishing SomnoMed in Canada, our customers will soon be able to order SomnoDent and SUAD devices from our Leamington, Canada location and benefit from streamlined shipping and a reduction in inter-country shipping fees. As COAT™ (Continuous Open Airway Therapy) treatment is becoming an increasingly accepted medical treatment for obstructive sleep apnea (OSA), it is important for companies to offer a broad line of products to fit specific patient types. The SUAD device is a very reputable product and suits a certain group of patients," said Dr. Kien Nguyen, President, SomnoMed North America.
SomnoMed Limited (ASX: SOM) is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea (OSA), snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards (FDA cleared and manufactured under ISO 13485 quality standards) have resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea (OSA). SomnoDent® is the most comfortable and effective design and treatment solution for over 250,000 patients in 26 countries.
For additional information, visit SomnoMed at www.somnomed.com.
Contact: Stacy Pinkerton, 972-377-3400, email@example.com